LIVERO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,679 JPY | +0.84% |
|
+4.61% | +63.65% |
| 2023 | Livero Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2023 | Tranche Update on Livero Inc.'s Equity Buyback Plan announced on February 20, 2023. | CI |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With a 2024 P/E ratio at 26.57 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Sector: Real Estate Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +63.65% | 55.64M | - | ||
| +1.68% | 28.55B | B+ | ||
| -3.58% | 18.97B | C- | ||
| -13.80% | 11.79B | C- | ||
| +19.56% | 10.74B | B+ | ||
| +3.39% | 7.34B | C- | ||
| +0.44% | 6.21B | B+ | ||
| +33.11% | 4.35B | - | - | |
| +11.02% | 2.75B | C+ | ||
| +125.38% | 2.49B | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
-
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 9245 Stock
- Ratings Livero Inc.
